In addition, the combination therapy of dapagliflozin with RSV has better glucose-lowering effects than the single SGLT2i therapy in T2D treatment, and the therapeutic effects of enhancing glucose production and inhibiting gluconeogenesis were also produced by modulating the PI3K/AKT pathway (Sun et al., 2021). The gene discussed is AKT1; the disease is type 2 diabetes mellitus.